SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neovasc, Inc. – NVCN

NEW YORK, NY / ACCESSWIRE / June 29, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Neovasc, Inc. (“Neovasc” or the Company) (NASDAQ: NVCN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

[Click here to join a class action]

The investigation concerns whether Neovasc and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 19, 2016, news outlets reported that a Massachusetts federal jury had awarded a $70 million verdict to Neovasc’s rival, CardiAQ Valve Technologies Inc. (“CardiAQ”), finding that Neovasc had stolen trade secrets from CardiAQ.

On this news, Neovasc’s share price fell $1.38, or 75%, to close at $0.46 on May 20, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 441824